Recommended Conferences

  • Oncology & Cancer
    March 12-14, 2018 Singapore
  • Oncology Research & Cancer Stem Cells
    May 10-12, 2018 Frankfurt, Germany
  • and Radiology
    June 1-2, 2018 Osaka,Japan
  • Gynecology & Gynecologic Oncology
    July 23-24, 2018 Rome, Italy
  • Cancer Science & Therapy
    August 09-10, 2018 Madrid, Spain
  • Cancer Research and Anticancer Therapies
    September 17-18, 2018 San Diego, USA
  • 36th World Cancer Conference
    October 11-13, 2018 Zurich, Switzerland

Dr. Lin Ye

Dr. Lin Ye
Cardiff University School of Medicine, UK.
After graduated from the Shandong University of Traditional Chinese Medicine with MB. BCh in 1993, I started my clinical work at the Department of Surgery in the University Hospital, Jinan, China. I had been a surgeon and clinical teacher for more than ten years before I move to Cardiff at the end of 2004, from then on I have started the current research on the mechanism of tumour spread and metastasis from prostate cancer and breast cancer. After my Ph.D study at Cardiff University School of Medicine, I had worked on a project as a postdoctoral fellow since May of 2007, which aimed to develop a novel anti-angiogenesis therapeutic approach for cancer. I have been appointed as a non-clinical lecturer of cancer biology at Cardiff University School of Medicine in December, 2011. I am currently working on studies to investigate roles played by BMP and BMP signaling in bone metastasis of breast and prostate cancer. Meanwhile I also work on some other research projects in collaboration with clinicians and scientists within UK, or from US and China.
Research Interest
Metastatic bone lesions frequently occur with certain solid tumours, and are the main type of metastasis of breast cancer, prostate cancer and lung cancer, 3 of the leading types of cancer. Due to the profound effects of bone morphogenetic proteins on bone formation and turnover, their involvement bone metastasis has attracted wide attention in the past decade. Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-?) superfamily first named by Urist (1965). BMP proteins were first purified and cloned by Wozney et al. (1988), Celeste et al. (1990), Lee (1990) and Ozkaynak et al. (1990), amongst others. 1. BMP signalling and the predisposition to metastasise to bone. 2. BMPs and colonisation of metastatic cancer cells in the bone. 3. BMP signalling events in cancer cells. 4. BMPs and epithelial-mesenchymal transition (EMT). 4. Therapeutic potential.

Relevant Conferences